This trial is active, not recruiting.

Condition acute rejection
Treatments rituximab, placebo
Phase phase 3
Target CD20
Sponsor Hannover Medical School
Collaborator German Federal Ministry of Education and Research
Start date May 2012
End date May 2017
Trial size 180 participants
Trial identifier NCT01117662, 200710602


Acute kidney allograft rejection is the major cause for a loss of graft function and has a negative impact on long-term graft survival. Anti-rejection therapy traditionally focuses on T cell-mediated mechanisms of renal allograft rejection. However, available agents that affect T-cell pathways have only little impact on long-term graft survival. There is increasing evidence that B-cells play an important role in acute transplant rejections. CD20+ B cell infiltrates in acute T-cell mediated rejections are frequent and correlate with a worse response to conventional anti-rejection treatment and an increased risk of graft loss. In one pilot study, supported by several case reports, a beneficial effect of Rituximab for the treatment of acute rejection episodes with intrarenal B-cell infiltrates was shown. However, despite the promise of these observations solid evidence is required before incorporating this treatment option into a general treatment recommendation.

In a multicenter randomized placebo controlled double blind phase III trial the investigators want to demonstrate that Rituximab in addition to standard treatment with steroid-boli is superior to the standard treatment alone regarding long-term kidney function. If the proposed study proves that Rituximab treatment of acute rejections is beneficial for the long-term allograft function, the conventional rejection therapy needs to be revised to this novel concept of B- cell targeting

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
rituximab MabThera
Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
(Placebo Comparator)
Intravenous application of placebo (NaCl 0,9 %) matching active treatment
Intravenous application of placebo (NaCl 0,9 %) matching active treatment

Primary Outcomes

Change of the GFR (glomerular filtration rate) one year after intervention compared to the baseline GFR before the rejection, which is calculated by a defined algorithm
time frame: Baseline, 1 year

Secondary Outcomes

Progression of interstitial fibrosis and tubular atrophy between the biopsy that led to enrolment in the study and a scheduled protocol biopsy one year after intervention ("∆IFTA-Score")
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion criteria: 1. male or female patients age ≥ 18 at the time of the inclusion in the study 2. male or female patients after kidney transplantation if medically justifiable (cave: previous immunosuppression, particularly prior induction therapies or biologicals). 3. Proof of an acute rejection in kidney transplant according to Banff-criteria: T-cell-mediated rejection as borderline, grade IA/B, IIA/B (no v-only), if one or more results are available as significant B-cell infiltrates CD20≥20 / high power field, glomerulitis, peritubular capillaritis or C4d positivity (with the exception of ABO-incompatible transplantations) as well as patients who have no T-cell-mediated acute rejection, but signs of acute humoral rejection (as listed above according to the criteria glomerulitis, peritubular capillaritis, C4d positivity) who have to be treated according to medical opinion of the physician with steroid therapy. The evidence of rejection can be performed by a protocol or indication biopsy. 4. SV40-negativity in the biopsy 5. GFR calculated using the MDRD-Formula > 25 ml/min/1,73 m² in the time period before the noticed rejection. 6. Presence of a negative pregnancy test and consent to a highly effective contraceptive method (i.e. failure rate less than 1% per year, which are implants, injectable contraceptives, combined oral contraceptives, intrauterine devices (only hormone spirals), sexual abstinence or vasectomy of the partner) in patients of child-bearing age. This is not required when bilateral sterilization or ovariectomy of the patient and in patients that have exclusively female sex partners. Presence of consent to a highly effective contraceptive method for male patient. 7. Informed consent Exclusion criteria: 1. Known contraindications, resp. incompatibility for Rituximab and/or for the concomitant medication 2. Administration of Rituximab within the last 12 months before inclusion 3. Simultaneous participation in an other clinical study or participation in an other clinical study within the last 30 days 4. Breastfeeding women or pregnant women 5. Persons who fail to assess essence, meaning and significance of the clinical study and act along these lines (according to § 40 Abs. 4 and § 41 Abs. 2 and Abs. 3 AMG) 6. Existence of an active CMV-infection, existence of a HIV-infection, existence of a replicative hepatitis B or C, existence of other grave infections 7. Cardiac insufficiency in phase NYHA III-IV 8. High grade cardiac arrhythmias 9. Unstable coronary heart disease 10. Poorly adjusted diabetes mellitus (HbA1c > 10 %) at the time of the inclusion in the study. 11. State after splenectomy 12. Contra-indication referring to a renewed transplant biopsy (e.g. coagulopathy, anticoagulation) 13. Other exclusion criteria according to the estimate of the attending doctor (e.g. aggravation of the general health condition, occurrence of a malignant disease)

Additional Information

Official title Efficacy of Rituximab in Acute Cellular Rejection With B-cell Infiltrates in Renal Transplant Patients - Randomized Placebo Controlled Double Blind Trial
Trial information was received from ClinicalTrials.gov and was last updated in October 2015.
Information provided to ClinicalTrials.gov by Hannover Medical School.